AstraZeneca’s Breast Cancer Drug Etcamah Gets US FDA Approval

{
  "signal_id": "d928a08d-13c1-8df9-c74f-66f98f93d2b7",
  "signal_type": "news",
  "signal_subtype": "launches",
  "detected_at": "2026-09-05T04:56:45+00:00",
  "company": {
    "name": "AstraZeneca",
    "domain": "astrazeneca.com"
  },
  "data": {
    "url": "https://www.freepressjournal.in/business/astrazenecas-breast-cancer-drug-etcamah-gets-us-fda-approval",
    "title": "AstraZeneca’s Breast Cancer Drug Etcamah Gets US FDA Approval - Free Press Journal",
    "excerpt": "AstraZeneca has secured approval from the US Food and Drug Administration (FDA) for its breast cancer treatment camizestrant, marking a significant milestone for the pharmaceutical company after the drug faced opposition from an advisory panel earlier this year. According to a report by Bloomberg, the medicine, which will be sold under the brand name Etcamah, was cleared through the FDA’s accelerated approval process. It can be prescribed along with other cancer treatments for patients with metastatic breast cancer carrying a specific genetic mutation linked to disease progression. AstraZeneca targets growth through oncology pipeline AstraZeneca believes Etcamah could become a major revenue contributor, estimating that the drug has the potential to generate more than $5 billion in annual sales. However, analysts remain more cautious, with current market forecasts projecting sales of about $2.3 billion by 2032. The approval follows an earlier setback when the FDA’s Oncology Drugs Advisory Committee voted against the treatment, stating that available evidence did not demonstrate a significant enough benefit for patients. However, the regulator later concluded that the drug could provide another treatment option for women battling advanced breast cancer. Etcamah functions as a hormone therapy by blocking estrogen from activating cancer cells, thereby slowing their growth...",
    "product": "Etcamah",
    "summary": "AstraZeneca received FDA approval for its breast cancer drug, camizestrant, which will be marketed under the brand name Etcamah.",
    "planning": false,
    "image_url": "https://media.assettype.com/freepressjournal/2020-11/76d07853-8e6d-4701-82d1-da011c60249d/astrazeneca1.jpg",
    "confidence": 0.95,
    "product_data": {
      "name": "Etcamah",
      "full_text": "breast cancer treatment camizestrant",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-09-05T04:56:45Z",
    "article_sentence": "AstraZeneca has secured approval from the US Food and Drug Administration (FDA) for its breast cancer treatment camizestrant, marking a significant milestone for the pharmaceutical company after the drug faced opposition from an advisory panel earlier this year."
  }
}

curl https://signals.autobound.ai/v1/signals/d928a08d-13c1-8df9-c74f-66f98f93d2b7 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"astrazeneca.com","limit":20}'